We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+0.96%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$824M
AUM Growth
-$51.7M
Cap. Flow
-$31.3M
Cap. Flow %
-3.8%
Top 10 Hldgs %
74.72%
Holding
32
New
1
Increased
8
Reduced
14
Closed
2

Top Buys

Rank Stock Value
1
AXDX
Accelerate Diagnostics
AXDX
+$13.4M
2
BLUE
bluebird bio
BLUE
+$4.43M
3
TTHI
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
+$3.27M
4
ARAY icon
Accuray
ARAY
+$3.26M
5
PACB icon
Pacific Biosciences
PACB
+$2.14M

Top Sells

Rank Stock Value
1
ECYT
Endocyte, Inc. Common Stock
ECYT
+$16M
2
THC icon
Tenet Healthcare
THC
+$10.7M
3
THOR
THORATEC CORPORATION
THOR
+$9.66M
4
QDEL icon
QuidelOrtho
QDEL
+$7.85M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$3.92M

Sector Composition

Rank Sector Weight
1 Healthcare 76.93%
2 Consumer Staples 0.18%
3 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXDX
1
DELISTED
Accelerate Diagnostics
AXDX
$140M 17.02%
539,406
+61,601
+13% +$13.4M
THC icon
2
Tenet Healthcare
THC
$20.1B
$71.3M 8.65%
1,518,876
-237,074
-14% -$10.7M
ACOR
3
DELISTED
Acorda Therapeutics
ACOR
$65.1M 7.9%
16,095
-208
-1% -$848K
QDEL icon
4
QuidelOrtho
QDEL
$1.21B
$64.5M 7.82%
2,915,633
-341,324
-10% -$7.85M
MZOR
5
DELISTED
Mazor Robotics Ltd.
MZOR
$55.4M 6.73%
3,154,281
-40,281
-1% -$716K
NXTM
6
DELISTED
NxStage Medical Inc.
NXTM
$53.5M 6.49%
3,723,407
+124,215
+3% +$1.62M
THOR
7
DELISTED
THORATEC CORPORATION
THOR
$51.1M 6.2%
1,466,304
-289,900
-17% -$9.66M
OPK icon
8
Opko Health
OPK
$978M
$50M 6.07%
5,655,738
+83,778
+2% +$732K
TTHI
9
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$32.6M 3.96%
4,851,321
+563,909
+13% +$3.27M
ARAY icon
10
Accuray
ARAY
$32.2M
$31.8M 3.86%
3,616,293
+376,287
+12% +$3.26M
HNSN
11
DELISTED
HANSEN MEDICAL, INC. COM NEW
HNSN
$25.6M 3.11%
1,954,654
-11,161
-0.6% -$194K
IRWD icon
12
Ironwood Pharmaceuticals
IRWD
$728M
$24.8M 3.02%
1,935,361
-268,769
-12% -$2.92M
RPRX
13
DELISTED
Repros Therapeutics Inc.
RPRX
$21.9M 2.66%
1,267,126
+24,800
+2% +$404K
TSRO
14
DELISTED
TESARO, Inc.
TSRO
$19.7M 2.39%
633,752
– –
PACB icon
15
Pacific Biosciences
PACB
$441M
$18.6M 2.25%
3,002,508
+426,779
+17% +$2.14M
VRML
16
DELISTED
Vermillion, Inc.
VRML
$18.4M 2.24%
7,139,960
– –
WBMD
17
DELISTED
WebMD Health Corp.
WBMD
$14.5M 1.76%
300,141
– –
BIOL
18
DELISTED
Biolase, Inc.
BIOL
$13.5M 1.64%
491
– –
PGEN icon
19
Precigen
PGEN
$2.36B
$9.26M 1.12%
385,574
-189,909
-33% -$3.85M
GTIV
20
DELISTED
GENTIVA HEALTH SERVICES INC
GTIV
$9.07M 1.1%
601,960
-245,640
-29% -$2.77M
BLUE
21
DELISTED
bluebird bio
BLUE
$6.9M 0.84%
+13,814
New +$4.43M
AMRN
22
Amarin Corp
AMRN
$297M
$6.51M 0.79%
185,000
+35,000
+23% +$1.1M
DSCI
23
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$5.7M 0.69%
492,796
-7,204
-1% -$73.9K
GILD icon
24
Gilead Sciences
GILD
$163B
$4.15M 0.5%
50,000
– –
AGEN
25
Agenus
AGEN
$326M
$3.74M 0.45%
59,160
-10,929
-16% -$632K
1
2

Similar funds

BIO
Blue Investment Opportunities Miami Beach, Florida $168M AUM 21.32% 1-Year Est. Return
OBWA
Oak Barrel Wealth Advisory Reston, Virginia $167M AUM
EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
HIA
Harvest Investment Advisors Tallahassee, Florida $176M AUM
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM

Oracle Investment Management's Q2 2014 Portfolio in Review

As of Q2 2014, Oracle Investment Management held 32 positions worth $824M, down 5.9% from $876M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Oracle Investment Management withdrew a net $31.3M in Q2 2014, closing 2 positions and reducing 14 holdings. Its most notable exit was Endocyte, Inc. Common Stock, an estimated $16M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 73% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Oracle Investment Management opened a new position in bluebird bio worth $6.9M.

  • Oracle Investment Management's largest Q2 2014 buy was bluebird bio: 13,814 shares worth $6.9M.
  • Oracle Investment Management added most to Accelerate Diagnostics in Q2 2014, an estimated $13.4M increase.
  • Oracle Investment Management's biggest Q2 2014 reduction was Tenet Healthcare, cutting an estimated $10.7M.
  • Oracle Investment Management fully exited Endocyte, Inc. Common Stock in Q2 2014, selling an estimated $16M.
  • Oracle Investment Management's ten largest holdings make up 75% of its $824M portfolio in Q2 2014.
  • Oracle Investment Management opened 1 new position and closed 2 in Q2 2014.
  • Oracle Investment Management's portfolio value fell 5.9% quarter-over-quarter to $824M.

Based on Oracle Investment Management's 13F filing for Q2 2014, filed 14 Aug 2014.